BGT007
/ Guangzhou Bioresette Biomedical, Biosyngen
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 16, 2024
BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies
(clinicaltrials.gov)
- P1 | N=15 | Not yet recruiting | Sponsor: BioSyngen Pte Ltd
New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
October 27, 2023
BGT007 Cells for the Treatment of Refractory Digestive System Tumors
(clinicaltrials.gov)
- P1 | N=14 | Recruiting | Sponsor: The Affiliated Hospital of Xuzhou Medical University
Metastases • New P1 trial • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor
November 28, 2022
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
(clinicaltrials.gov)
- P1 | N=23 | Recruiting | Sponsor: The Affiliated Hospital of Xuzhou Medical University | Not yet recruiting ➔ Recruiting
Enrollment open • Nasopharyngeal Carcinoma • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1